Mankind Pharma launches drug to deal with diabetes, coronary heart failure and CKD

0
541

Mankind Pharma has launched Justoza, a brand of dapagliflozin marketed by Mankind for the treatment of diabetes, heart failure and chronic kidney disease. The active pharmaceutical ingredient is obtained from the DMF (Drug Master File) facility approved by the US FDA, EU GMP and WHO GMP, which guarantees the highest standards of effectiveness and safety worldwide. It is believed that the quality of DMF quality equipment products is of the highest standard in terms of safety and effectiveness.

Commenting on the launch, Atish Majumdar, President of Mankind Pharma said: “The introduction of API DMF Grade Dapagliflozin is an innovative, futuristic approach to bringing the best quality in its class to patients. This is just the beginning, we aim to add more drugs to the list. Serving life is a mission in progress for us at Mankind Pharma. “